PYX Resources: Achieving volume and diversification milestones. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Is this new?
by functional T cell responses to the TRP2 and gp100 peptides which can be detected in patients post vaccination
Not really relevant, given market caps and failing companies…..
British biotech start-up backed by Snoop Dogg has unveiled plans to ditch the “turbulent” London stock market, dealing a fresh blow to the beleaguered exchange.
Oxford Cannabinoid Technologies said it was delisting from London following a “continuous, irrational and regressive pressure” on its share price. The company claimed it would be much better valued as a private company and would also not have to bear the “substantial cost” of maintaining a public listing.
Clarissa Sowemimo-Coker, chief executive of Oxford Cannabinoid Technologies, said: “It has been a turbulent time on the capital markets pretty much since we listed. The last 12 to 24 months have been especially challenging for small caps and particularly in the biopharma space. Companies have lost 80pc or 90pc of their value and once you’re down there, it’s very difficult to make any inroads to start climbing back up again.”
She said this was having knock-on effects when it came to bringing new treatments to market: “Things do take longer when you’re trying to stretch for capital. You inevitably slow down drug development.”
Ms Sowmimo added: “We anticipate that as an unlisted company, a far larger pool of capital may be available to us, and therefore it is right for us to make this change.”
The British biotech, which landed a $10m (£8m) cash injection from Snoop Dogg five years ago, joined the London Stock Exchange in 2021. Since then, it has lost 97pc of its value. The company said it expected to go public again “in due course” but that it was more likely that this would be in the US.
Ms Sowmimo-Coker said: “We’re intending to go away for a few years and we’d hope that the London markets will have undergone a rejuvenation by then. But also Nasdaq is an opportunity and lots of others are going there.”
Ms Sowminmo-Coker said there was a “fair bit of red tape” in the market and also called for more to be done on bolstering institutional investment into companies following years of dwindling support.
The announcement will add to growing concerns over the future of the London market, which has been battling a wave of company exits in recent months. Biotechnology companies, in particular, have been vocal in their criticism of London’s public markets, which bosses have claimed is preventing early-stage research businesses from being able to spend on new treatments.
Last month, Redx Pharma said it was quitting the Alternative Investment Market (AIM), claiming its low valuation was “not conducive” to raising cash to spend on more treatments.
C4X Discovery also unveiled plans to leave AIM earlier this year, saying the recent downturn in the financial markets “adversely impacted our share price, and with it, our future ability to raise funds in the public markets”.
It prompted a warning from Sir John Bell, one of Britain’s top life sciences leaders, that more drug makers could follow. He branded the City
Intresting X tweets.
Jan 3
Feb 2
March 1
April 0
today 2
something coming, I hope so
Been a long time since an update
Gosh ... even after investing in Scancell for decades the science is still beyond my comprehension when I read some of the articles related to the science. However.. I understand a raising share price which is great to see : ))
I wonder what information Scancell will be sharing....mmm
Https://twitter.com/scancellpharma/status/1788129533649981798
May is #MelanomaAwareness month. Over the next few weeks, we will be sharing information about the science behind melanoma and how our therapeutic approach has the potential to provide better treatment options for patients. For more: https://aacr.org/patients-caregivers/awareness-months/melanoma-and-skin-cancer-awareness-month/
#CancerVaccines
I see they went to a low of 8.92p on 30/4/24.
Back to level of last top up today 8% spread.
As I posted 25 April 2023 last year, this can be a costly site to read .
Thanks for reply EE.
Yes BoD wise, we are lean, mean and ready to go!
If only. ATB
Seller done, I think. There was a trade last Thursday (I think) which looked like a clearing of position.
One point I’d note on the “what he’s up to” question from tf…..
…..many corporate mergers fail due to having too many executives for the post-merger number of executive chairs available. I don’t think that will be a problem with Scancell……
After weeks where size of offer was reasonable not much on the offer and not much of a discount. Seller done or maybe wants a higher price?
Https://www.rootsanalysis.com/reports/fc-protein-engineered-and-glycoengineered-antibodies-market.html
Global Fc and Glycoengineered Antibodies Market Size
The global Fc and glycoengineered antibodies market is estimated to be worth US$ 38.8 billion in 2024. Driven by the increasing potential of these engineered antibodies as therapeutic agents, the market is anticipated to grow at a notable rate during the forecast period. Further, in terms of type of engineering, Fc engineered antibodies are likely to capture majority (93%) of the share, followed by glycoengineered antibodies (7%) within the overall market, by 2035.
Frequently Asked Questions
Question 1: What is Fc region engineered antibodies?
Answer: Engineered antibodies, developed by modifying the fragment crystallizable (Fc) region, are termed as Fc region engineered antibodies. The modifications in the Fc region of an antibody have been shown to augment the various effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Question 2: How big is the Fc and glycoengineered antibodies market?
Answer: The Fc and glycoengineered antibodies market size is anticipated to be worth $38.8 billion in 2024.
Question 3: Who are the leading players developing Fc and glycoengineered antibodies?
Answer: Examples of key companies engaged in Fc and glycoengineered antibodies industry (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie, Akesobio, Alexion Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim, Genentech, MacroGenics, MorphoSys, Kyowa Kirin and Xencor.
Question 4: How many Fc and glycoengineered antibodies are currently marketed?
Answer: Around 20 Fc and glycoengineered antibodies are currently marketed across different therapeutic indications.
Question 5: How many companies are currently engaged in the Fc and glycoengineered antibodies market?
Answer: Over 30 companies are currently engaged in the Fc and glycoengineered antibodies industry.
Question 6: Which type of engineering are mainly used to develop Fc and glycoengineered antibodies by various developers?
Answer: At present, majority (93%) of the developers are using Fc engineering to develop Fc and glycoengineered antibodies.
Question 7: Which type of therapy is popular for the development of different Fc and glycoengineered antibodies?
Answer: In the realm of Fc and glycoengineered antibodies, monotherapies are mainly focused, sharing 46% share in the current market.
Question 8: Which target therapeutic area occupies the largest market share of the Fc and glycoengineered antibodies market?
Answer: In 2024, oncological disorders has the largest market share (39%) of the Fc and glycoengineered antibodies market.
Question 9: What is the most common route of administration used for Fc and glycoengineered antibodies?
Answer: Currently, intravenous rou
Thanks Bermuda - interesting possibilities for 'Glycans' and for all 4 of Scancell's platforms . . . . I wonder which of the four will cross the line first, the 'line' being some new commercial action ?
Thanks Johnny. That's good. Noting that Sath is the second of our 2 Executive Directors, he's obviously doing well at Scancell. I wonder what he's up to apart from the routine work ?
I see that with effect from 30 April’24 Keith Green is no longer the Company Secretary and Sath Nirmalananthan is now in that role:-
https://find-and-update.company-information.service.gov.uk/company/06564638/filing-history
Scancell’s website has also been updated to show this:-
https://www.scancell.co.uk/company
Lofas and Team Astute must be livid.
Can't moan and/or offer "balance".
While it's quiet the paper below is worth a read.
CAR T therapy has been hugely successful in blood cancers but nobody has yet managed to crack CAR T for solid tumours. In the link below the researchers are exploring ways of improving CAR T through identification of new solid tumour targets and in particular glycans. A couple of quotes:-
'Carbohydrate antigens often exhibit low immunogenicity and typically elicit T-independent immune responses, posing an obstacle to T-cell engagement. Despite these limitations, the implication of TACAs (tumor-associated carbohydrates antigens) in cancer biology has recently sparked significant interest in their potential as targets for immunotherapy. '
'the large number of experimental approaches to circumvent these difficulties, including many studies that are underway, some already in clinical trials, suggest a bright future for CAR-T therapy for solid tumors. Given the limitations of target antigens, tumor-associated carbohydrates are increasingly being explored as optimal targets for this therapy. These carbohydrates can be highly tumor-specific, while being shared among tumors from different individuals and different tissues of origin; therefore, CAR-T cell therapy may have a promising “sweeter” future.'
https://www.mdpi.com/2073-4409/13/9/725
YAY...some blue 💙
Don’t ofer pointers pointing to nowhere. No need to say anything if there is nothing to say …. Policy adapted by Scancell .
Https://www.independent.co.uk/news/health/covid-vaccine-research-pandemic-uk-b2539136.html
And what do you have to offer Lofas? Confusion, contradiction and FUD perhaps? For someone who has written this share off you seem awfully interested.
I'm pretty sure CW is not a "him" by the way. But there you go go again, shooting your mouth off without a clue.
…and all is under the research banner. Between him and inanaco they contribute 99% of the white noise.
100%
CW as always keeps on posting and creating chats on subjects with no direct connection. What a waste of time and space.